<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.3">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Genet Med</journal-id>
      <journal-id journal-id-type="iso-abbrev">Genet Med</journal-id>
      <journal-title-group>
        <journal-title>Genetics in Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1098-3600</issn>
      <issn pub-type="epub">1530-0366</issn>
      <publisher>
        <publisher-name>Nature Publishing Group US</publisher-name>
        <publisher-loc>New York</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">34230638</article-id>
      <article-id pub-id-type="pmc">8553619</article-id>
      <article-id pub-id-type="publisher-id">1264</article-id>
      <article-id pub-id-type="doi">10.1038/s41436-021-01264-0</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Brief Communication</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Missense <italic>NAA20</italic> variants
impairing the NatB protein N-terminal acetyltransferase cause autosomal recessive
developmental delay, intellectual disability, and microcephaly</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Morrison</surname>
            <given-names>Jennifer</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Altuwaijri</surname>
            <given-names>Norah K.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Br&#xF8;nstad</surname>
            <given-names>Kirsten</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Aksnes</surname>
            <given-names>Henriette</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Alsaif</surname>
            <given-names>Hessa S.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Evans</surname>
            <given-names>Anthony</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hashem</surname>
            <given-names>Mais</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wheeler</surname>
            <given-names>Patricia G.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Webb</surname>
            <given-names>Bryn D.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Alkuraya</surname>
            <given-names>Fowzan S.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes" equal-contrib="yes">
          <name>
            <surname>Arnesen</surname>
            <given-names>Thomas</given-names>
          </name>
          <address>
            <email>thomas.arnesen@uib.no</email>
          </address>
          <xref ref-type="aff" rid="Aff3">3</xref>
          <xref ref-type="aff" rid="Aff5">5</xref>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.413939.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0456 3548</institution-id><institution>Division of Genetics, </institution><institution>Arnold Palmer Hospital, </institution></institution-wrap>Orlando, FL USA </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.415310.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 2191 4301</institution-id><institution>Department of Translational Genomics, Center for Genomic
Medicine, </institution><institution>King Faisal Specialist Hospital and Research Center, </institution></institution-wrap>Riyadh, Saudi Arabia </aff>
        <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.7914.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7443</institution-id><institution>Department of Biomedicine, </institution><institution>University of Bergen, </institution></institution-wrap>Bergen, Norway </aff>
        <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.59734.3c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0670 2351</institution-id><institution>Department of Genetics and Genomic Sciences, </institution><institution>Icahn School of Medicine at Mount Sinai, </institution></institution-wrap>New York, NY USA </aff>
        <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.7914.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7443</institution-id><institution>Department of Biological Sciences, </institution><institution>University of Bergen, </institution></institution-wrap>Bergen, Norway </aff>
        <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.412008.f</institution-id><institution-id institution-id-type="ISNI">0000 0000 9753 1393</institution-id><institution>Department of Surgery, </institution><institution>Haukeland University Hospital, </institution></institution-wrap>Bergen, Norway </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>6</day>
        <month>7</month>
        <year>2021</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>6</day>
        <month>7</month>
        <year>2021</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2021</year>
      </pub-date>
      <volume>23</volume>
      <issue>11</issue>
      <fpage>2213</fpage>
      <lpage>2218</lpage>
      <history>
        <date date-type="received">
          <day>10</day>
          <month>5</month>
          <year>2021</year>
        </date>
        <date date-type="rev-recd">
          <day>15</day>
          <month>6</month>
          <year>2021</year>
        </date>
        <date date-type="accepted">
          <day>16</day>
          <month>6</month>
          <year>2021</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2021</copyright-statement>
        <license>
          <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
          <license-p><bold>Open Access</bold> This article is licensed
under a Creative Commons Attribution 4.0 International License, which permits
use, sharing, adaptation, distribution and reproduction in any medium or format,
as long as you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons license, and indicate if changes were
made. The images or other third party material in this article are included in
the article&#x2019;s Creative Commons license, unless indicated otherwise in a
credit line to the material. If material is not included in the
article&#x2019;s Creative Commons license and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will need to
obtain permission directly from the copyright holder. To view a copy of this
license, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Purpose</title>
          <p id="Par1">N-terminal acetyltransferases modify proteins by adding an acetyl
moiety to the first amino acid and are vital for protein and cell function. The
NatB complex acetylates 20% of the human proteome and is composed of the
catalytic subunit NAA20 and the auxiliary subunit NAA25. In five individuals
with overlapping phenotypes, we identified recessive homozygous missense
variants in <italic>NAA20</italic>.</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p id="Par2">Two different <italic>NAA20</italic> variants were
identified in affected individuals in two consanguineous families by exome and
genome sequencing. Biochemical studies were employed to assess the impact of the
<italic>NAA20</italic> variants on NatB complex formation
and catalytic activity.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p id="Par3">Two homozygous variants, <italic>NAA20</italic>
p.Met54Val and p.Ala80Val (GenBank: NM_016100.4, c.160A&gt;G and
c.239C&gt;T), segregated with affected individuals in two unrelated
families presenting with developmental delay, intellectual disability, and
microcephaly. Both NAA20-M54V and NAA20-A80V were impaired in their capacity to
form a NatB complex with NAA25, and in vitro acetylation assays revealed reduced
catalytic activities toward different NatB substrates. Thus, both NAA20 variants
are impaired in their ability to perform cellular NatB-mediated N-terminal
acetylation.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p id="Par4">We present here a report of pathogenic <italic>NAA20</italic> variants causing human disease and data supporting an
essential role for NatB-mediated N-terminal acetylation in human development and
physiology.</p>
        </sec>
        <sec>
          <title>Graphical Abstract</title>
          <p id="Par5">
<graphic position="anchor" xlink:href="41436_2021_1264_Figa_HTML" id="d32e424"/>
</p>
        </sec>
      </abstract>
      <funding-group>
        <award-group>
          <funding-source>
            <institution-wrap>
              <institution-id institution-id-type="FundRef">https://doi.org/10.13039/</institution-id>
              <institution>Research Council of
Norway</institution>
            </institution-wrap>
          </funding-source>
          <award-id>249843</award-id>
          <award-id>249843</award-id>
          <principal-award-recipient>
            <name>
              <surname>Arnesen</surname>
              <given-names>Thomas</given-names>
            </name>
          </principal-award-recipient>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>
            <institution-wrap>
              <institution-id institution-id-type="FundRef">https://doi.org/10.13039/http://dx.doi.org/10.13039/100008730</institution-id>
              <institution>Kreftforeningen</institution>
            </institution-wrap>
          </funding-source>
          <award-id>171752&#x2014;PR-2009-0222</award-id>
          <principal-award-recipient>
            <name>
              <surname>Arnesen</surname>
              <given-names>Thomas</given-names>
            </name>
          </principal-award-recipient>
        </award-group>
      </funding-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; American College of Medical Genetics and Genomics 2021</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>INTRODUCTION</title>
      <p id="Par6">N-terminal acetylation is a common protein modification in eukaryotes,
and approximately 80% of all human proteins carry this modification [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Although not fully understood, N-terminal acetylation may have a
range of functional consequences for the modified proteins including
stability/degradation, subcellular targeting, and complex formation [<xref ref-type="bibr" rid="CR1">1</xref>]. NatB is one of the major eukaryotic
N-terminal acetyltransferases (NATs) acetylating around 20% of the human proteome in
a cotranslational manner. Proteins harboring Met-Glu-, Met-Asp-, Met-Gln-, and
Met-Asn-N-termini are substrates of NatB [<xref ref-type="bibr" rid="CR3">3</xref>]. The catalytic subunit NAA20 forms a stable heterodimer with
the large ribosomal anchor subunit NAA25 [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. NatB activity
has been linked to cancer cell survival and progression [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR6">6</xref>,
<xref ref-type="bibr" rid="CR7">7</xref>] as well as shutoff activity of
influenza A virus and viral polymerase activity [<xref ref-type="bibr" rid="CR8">8</xref>] and NAD<sup>+</sup>/NADH metabolism
[<xref ref-type="bibr" rid="CR9">9</xref>]. However, no genetic disease has
so far been linked to pathogenic variants of the <italic>NAA20</italic> or <italic>NAA25</italic> genes.</p>
      <p id="Par7">We report here five affected individuals of two unrelated families
presenting with developmental delay (DD), intellectual disability (ID), and
microcephaly. Homozygous <italic>NAA20</italic> variants (MIM
610833) segregated with the phenotypes. Protein studies revealed impaired
functionality of both identified variants supporting that reduced cellular
N-terminal acetylation is causative for disease.</p>
    </sec>
    <sec id="Sec2" sec-type="materials|methods">
      <title>MATERIALS AND METHODS</title>
      <p id="Par8"><italic>NAA20</italic> variants were discovered
through exome or genome sequencing after clinical evaluation. Contact between
clinicians and researchers was mediated by GeneDx/GeneMatcher [<xref ref-type="bibr" rid="CR10">10</xref>]. For further experimental details,
see&#xA0;<xref rid="MOESM1" ref-type="media">Supplemental Materials and
Methods</xref>.</p>
    </sec>
    <sec id="Sec3" sec-type="results">
      <title>RESULTS</title>
      <sec id="Sec4">
        <title>Genetic findings</title>
        <p id="Par9">The index case in family 1, a 13-year-old female (F1:V.2)
(Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1a</xref>) of Saudi origin,
was referred for neuropsychological evaluation for baseline cognitive assessment
because of her global DD and significant ID. She is the eldest of three
siblings, with a healthy sister and a brother similarly suffering from DD and ID
(F1:V.4). Parents are both healthy and are paternal cousins. Exome sequencing
performed on DNA from the two affected siblings uncovered a homozygous missense
variant of uncertain significance in <italic>NAA20</italic>
(NM_016100.5): c.160A&gt;G (p.Met54Val) (GenBank: NM_016100.4). We employed
both positional mapping to highlight candidate common regions within the genomes
of the affected and exome sequencing to identify the most likely candidate
variant(s) within these critical loci. Upon analyzing the family&#x2019;s
genotyping data, we identified eight regions of homozygosity (ROHs) that were
exclusively shared between the two affected siblings. We prioritized novel/rare
(minor allele frequency [MAF]&#x2009;&lt;&#x2009;0.001 based on gnomAD
and 2,379 local exomes), homozygous, coding/splicing variants within these
regions that minimized the search to the single <italic>NAA20</italic> variant. Segregation analysis of the variant confirmed
that both parents were heterozygous, whereas both affected siblings were
homozygous (Fig.&#xA0;<xref rid="MOESM1" ref-type="media">S1</xref>). The in
silico prediction of this variant suggests its likely deleterious nature using
BayesDel_addAF, CADD, FATHMM-MKL, LIST-S2, MutationTaster, and PrimateAI
(Table&#xA0;<xref rid="MOESM1" ref-type="media">S1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><title>Rare <italic>NAA20</italic> variants
segregating with developmental phenotypes in two
families.</title><p>(<bold>a</bold>) Pedigrees of family
1 and family 2 with affected members indicated as filled circles
(females) or squares (males). Triangle: pregnancy not carried to
term. Double horizontal lines indicate consanguinity. Wt and mut
indicate absence or presence of the <italic>NAA20</italic> variants, respectively. (<bold>b</bold>) Three-dimensional structure model
of NAA20 and NAA25 visualizing the positions of the variant
sites in the wildtype NAA20 structure. Gray, NAA25; blue, NAA20;
green, Ac-CoA; yellow, substrate peptide.</p></caption><graphic xlink:href="41436_2021_1264_Fig1_HTML" id="d32e546"/></fig></p>
        <p id="Par10">In family 2, three affected siblings (F2:II.1, F2:II.3, F2:II.4) of
Iraqi origin who were born to consanguineous parents presented for clinical
genetics evaluation due to history of DD and microcephaly
(Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1a</xref>). Chromosomal
microarray for the three affected siblings revealed common areas of absence of
heterozygosity (AOH) at hg19 coordinates chr20:10,418,800-16,923,134 and
chr20:29,448,795-41,483,591. Genome sequencing identified a homozygous missense
variant of unknown significance in <italic>NAA20</italic>
(c.239C&gt;T [p.Ala80Val] [GenBank: NM_016100.4]) in the three affected
siblings (Fig.&#xA0;<xref rid="MOESM1" ref-type="media">S1</xref>;
<xref rid="MOESM1" ref-type="media">Supplemental Materials and
methods</xref>).</p>
        <p id="Par11">The <italic>NAA20</italic> c.239C&gt;T
(p.Ala80Val) variant is predicted to be deleterious using BayesDel_addAF, CADD,
DANN, EIGEN, FATHMM-MKL, LIST-S2, MutationTaster, PrimateAI, and SIFT
(Table&#xA0;<xref rid="MOESM1" ref-type="media">S1</xref>). Neither of
these two <italic>NAA20</italic> variants were contained in
gnomAD.</p>
      </sec>
      <sec id="Sec5">
        <title>Clinical findings</title>
        <p id="Par12">The clinical findings of the five affected individuals are
partially overlapping and are summarized in Table&#xA0;<xref rid="MOESM1" ref-type="media">S2</xref> and in the Supplemental <xref rid="MOESM1" ref-type="media">case reports</xref>.</p>
        <p id="Par13">DD was present in all affected individuals. Head circumference was
reduced, with microcephaly (between -2.3&#x2009;SD and -3.5&#x2009;SD) for
four individuals and borderline microcephaly for F1:V.4 (-1.9&#x2009;SD).
Ability to walk was delayed and observed at 2&#x2013;3.5 years. All individuals
have a limited ability to speak. The female proband of family 2 (F2:II.1) only
uses a few words appropriately at age 10 years. Vision and hearing appear to be
normal for all. Some variable dysmorphic features are observed for 4/5
individuals, such as prominent philtrum, thick upper lips and epicanthal folds,
downslanting of palpebral fissures, and wide-spaced teeth. Mild to moderate ID
is observed for all cases, and autistic features are noted for 2/5 individuals
(one in each family). For all three affected individuals in family 2, but none
of the affected individuals in family 1, cardiac anomalies were observed.
F2:II.1 and F2:II.3 have ventricular septal defects, while F2:II.4 has patent
ductus arteriosus.</p>
      </sec>
      <sec id="Sec6">
        <title>Functional analysis of <italic>NAA20</italic>
variants</title>
        <p id="Par14">To define whether and how these two <italic>NAA20</italic> variants impair NAA20 protein function, we further
investigated their structural and biochemical properties. Both NAA20 Met54 and
Ala80 are evolutionarily conserved residues in many eukaryotic species
suggesting functional importance (Fig.&#xA0;<xref rid="MOESM1" ref-type="media">S2</xref>). Met54 and Ala80 are structurally positioned in the
vicinity of NAA25, the binding partner of NAA20 in the functionally active NatB
complex (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1b</xref>). Thus, it is
possible that altering these residues may impact the ability of NAA20 to bind
NAA25.</p>
        <p id="Par15">To investigate the potential impact of the variants on NatB complex
formation, NAA20-WT-V5, or variants were immunoprecipitated from HeLa cells.
Western blotting analysis revealed that both NAA20-M54V and NAA20-A80V
coimmunoprecipitated less NAA25 as compared to NAA20-WT
(Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2a, b</xref>). The defect of
NAA20-M54V was consistently more severe than that of NAA20-A80V. We found no
difference in the cellular stability of the two NAA20 variants as compared to
NAA20-WT by cycloheximide chase assay (Fig.&#xA0;<xref rid="MOESM1" ref-type="media">S3</xref>). This was further supported by the fact that NAA20 levels
were unchanged in lymphoblasts in all affected individuals of family 2 as
compared to control lymphoblasts (Fig.&#xA0;<xref rid="MOESM1" ref-type="media">S4</xref>). Importantly, we defined the intrinsic catalytic
N-terminal acetyltransferase activity of the two variants in vitro
(Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2c</xref>). We here assessed
the activity toward peptides representing all four types of NatB substrates,
Met-Glu-, Met-Asp-, Met-Gln-, and Met-Asn-. While NAA20-M54V exhibited a reduced
NatB activity toward all four substrate classes, NAA20-A80V displayed
alterations in a substrate-specific manner. NAA20-A80V was not reduced in its
capacity to acetylate a Met-Asp substrate, but it revealed a significant loss in
its capacity to acetylate Met-Glu, Met-Asn, and Met-Gln substrates
(Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2c</xref>). Since the
catalytic subunit NAA20 depends on complex formation with NAA25 to form the
active NatB complex on the ribosome, impaired binding between NAA20 and NAA25
will result in less active NatB complexes capable of modifying nascent
polypeptides, including those starting with Met-Asp. In addition, the decreased
intrinsic activities of NAA20-M54V and NAA20-A80V will further reduce the
cellular N-terminal acetylation of many NatB substrates. In sum, both NAA20
variants are less competent than NAA20-WT in performing cellular NatB-mediated
N-terminal acetylation of Met-Glu-, Met-Asp-, Met-Gln-, and
Met-Asn-N-termini.<fig id="Fig2"><label>Fig. 2</label><caption><title>NAA20-M54V and A80V have impaired capacity to form NatB
complexes and to catalyze NatB-mediated N-terminal
acetylation.</title><p>(<bold>a</bold>) HeLa cells were
transfected with Ctrl-V5 and NAA20-V5 constructs, lysed, and
immunoprecipitated with anti-V5. Lysate (lower) and
immunoprecipitation (IP) samples (upper) were immunoblotted with
anti-V5 and anti-NAA25. Image shown is the representative result
of nine independent experiments. (<bold>b</bold>) Quantification of NatB complex formation
based on immunoprecipitation experiments as shown in (<bold>a</bold>) (<italic>n</italic>&#x2009;=&#x2009;9). Ratio NAA25
immunoprecipitated by NAA20. Data are presented as mean
+/&#x2212; s.d.
****<italic>p</italic>&#x2009;&lt;&#x2009;0.00005 by
two-tailed <italic>t</italic>-test with
unequal variance. (<bold>c</bold>) NAA20-V5
wild type (WT) or variants were expressed in HeLa cells and
isolated by IP. IP product was used as input in N-terminal
acetylation assays using synthetic peptides representing one of
four NatB type substrates (Met-Asp, Met-Glu, Met-Asn, Met-Gln)
and [14&#x2009;C]-Acetyl Coenzyme A. Data from three
independent experiments were pooled. Reaction mix with control
(Ctrl) IP products served as blank and was subtracted.
V5-control plasmid was used for negative Ctrl. Values are
corrected for immunoblot band intensity and expressed as
relative to the WT. Data are presented as mean
+/&#x2212; s.d. Error bars show standard deviation.
*<italic>p</italic>&#x2009;&lt;&#x2009;0.05;
**<italic>p</italic>&#x2009;&lt;&#x2009;0.005;
***<italic>p</italic>&#x2009;&lt;&#x2009;0.0005;
****<italic>p</italic>&#x2009;&lt;&#x2009;0.00005 by
two-tailed <italic>t-</italic>test with
unequal variance. (<bold>d</bold>) Schematic
model of <italic>NAA20</italic>-related
syndrome. At the molecular level, NAA20-M54V weakly associates
with NAA25 while NAA20-A80V is only moderately impaired in NatB
complex formation. The formed NatB complexes of NAA20-M54V are
additionally impaired in catalyzing N-terminal acetylation of
all NatB type substrates, while NatB complexes of NAA20-A80V
display normal activity toward Met-Asp N-termini and impaired
activity toward Met-Glu, and in particular Met-Asn, and Met-Gln
N-termini. The decreased capacity to acetylate various N-termini
of cellular proteins has diverse pathophysiological effects such
as developmental delay, intellectual disability, and
microcephaly. For NAA20-A80V cases, cardiac anomalies are also
observed, but identification of further individuals is required
to define this as a phenotype typical for NAA20-related syndrome
or a specific subgroup defined by specific substrate
targeting.</p></caption><graphic xlink:href="41436_2021_1264_Fig2_HTML" id="d32e674"/></fig></p>
      </sec>
    </sec>
    <sec id="Sec7" sec-type="discussion">
      <title>DISCUSSION</title>
      <p id="Par16">Based on our functional studies, it is highly likely that the
individuals homozygous for the <italic>NAA20</italic>
c.160A&gt;G (p.Met54Val) or <italic>NAA20</italic>
c.239C&gt;T (p.Ala80Val) variants suffer from impaired NatB-mediated N-terminal
acetylation of numerous cellular substrates. Because there are several thousand
different NatB substrates in human cells [<xref ref-type="bibr" rid="CR3">3</xref>] and because NatB steers many cellular pathways [<xref ref-type="bibr" rid="CR1">1</xref>], pathogenic <italic>NAA20</italic> variants are likely to have pleiotropic effects. This fits
well with the overall findings of DD and ID in all individuals. However, NAA20-M54V
and NAA20-A80V displayed differences in their substrate specificities, with
NAA20-M54V relatively more impaired in its ability to acetylate Met-Asp substrates
while NAA20-A80V was comparatively less active toward the other substrate types
(Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2c</xref>). This might suggest
that there are also certain cellular NatB substrates that are specifically impacted
for each of these two <italic>NAA20</italic> variants. Thus,
unique clinical findings for affected individuals harboring a specific <italic>NAA20</italic> variant may relate to disrupted signaling via
specific NatB substrates only impaired for a specific variant
(Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2d</xref>). For example, only
affected family 2 individuals, not affected family 1 individuals, presented with
cardiac anomalies (Table&#xA0;<xref rid="MOESM1" ref-type="media">S2</xref>).
However, more individuals need to be identified to properly define the
genotype&#x2013;phenotype relationship, and differences in genetic background
between individuals may significantly contribute to observed phenotypic
differences.</p>
      <p id="Par17">In humans, seven distinct NAT enzymes (NatA&#x2013;NatF and NatH) have
been identified [<xref ref-type="bibr" rid="CR1">1</xref>]. Each NAT is
composed of unique subunits and catalyzes N-terminal acetylation of a unique set of
substrates. NatA&#x2013;NatE perform cotranslational N-terminal acetylation. While
NatA, NatB, and NatC perform bulk acetylation of large substrate pools, NatD and
NatE have more specialized roles toward a few substrates. In contrast, NatF and NatH
act post-translationally toward transmembrane proteins and actins, respectively
[<xref ref-type="bibr" rid="CR1">1</xref>].</p>
      <p id="Par18">Until now, pathogenic variants were only identified for genes encoding
the catalytic NAA10 and auxiliary NAA15 subunits of the NatA complex. In 2011, the
lethal X-linked Ogden syndrome was presented. Eight boys harboring a <italic>NAA10</italic> missense variant displayed an aged appearance,
craniofacial anomalies, hypotonia, global DD, cryptorchidism, and cardiac
arrhythmias [<xref ref-type="bibr" rid="CR11">11</xref>]. Investigations in
budding yeast and patient cells suggested that a reduced NatA mediated N-terminal
acetylation was involved in disease etiology [<xref ref-type="bibr" rid="CR12">12</xref>&#x2013;<xref ref-type="bibr" rid="CR14">14</xref>]. In
the last decade, a number of additional pathogenic <italic>NAA10</italic> variants were identified in boys and girls presenting with ID,
DD, and cardiac abnormalities [<xref ref-type="bibr" rid="CR15">15</xref>&#x2013;<xref ref-type="bibr" rid="CR17">17</xref>]. Distinct phenotypes such as Lenz microphthalmia syndrome
(MIM 309800) were also correlated to specific effects of some variants. The
potential multifunctionality of NAA10 as a monomeric NAT and KAT in addition to its
role as a catalytic subunit of the NatA complex (together with NAA15) makes it very
challenging to define disease mechanisms [<xref ref-type="bibr" rid="CR1">1</xref>], although some variants are more impaired in NatA function
while others are more impaired in monomeric NAA10 function. More recently, patients
harboring pathogenic <italic>NAA15</italic> variants also
presented with phenotypes partially overlapping with those observed for <italic>NAA10</italic> variants, including cohorts of patients with
congenital heart disease and autism spectrum disorder [<xref ref-type="bibr" rid="CR17">17</xref>&#x2013;<xref ref-type="bibr" rid="CR20">20</xref>].
Thus, it is likely that impaired NatA mediated N-terminal acetylation is at least in
part causative for disease seen in these individuals. Despite the fact that NatA and
NatB acetylate unique subsets of cellular substrates, at present, it is difficult to
distinguish between NatA and NatB-mediated impairment of N-terminal acetylation at
the level of human pathophysiology. This is due to the pleiotropic nature of
overlapping phenotypes as well as extensive phenotype variability among individuals
with pathogenic <italic>NAA10</italic>, <italic>NAA15</italic>, and <italic>NAA20</italic> variants.
Microcephaly is potentially a distinguishing parameter that is only found in some
<italic>NAA10</italic> and <italic>NAA15</italic> variant cases [<xref ref-type="bibr" rid="CR17">17</xref>], but was found in this study among all affected individuals with
<italic>NAA20</italic> variants (Table&#xA0;<xref rid="MOESM1" ref-type="media">S2</xref>). Unlike <italic>NAA10</italic> and <italic>NAA15</italic>, <italic>NAA20</italic> appears to be more tolerant to haploinsufficiency
(probability of loss of function intolerance [pLI] = 0.01) and less constrained for
missense variation (<italic>Z</italic> = 0.31). These
characteristics are consistent with the strictly recessive inheritance of the
variants we report in this study in <italic>NAA20</italic> in
contrast to the monoallelic disease-causing variants reported previously in
<italic>NAA10</italic> and <italic>NAA15</italic>.</p>
      <p id="Par19">In conclusion, we present here pathogenic <italic>NAA20</italic> variants that disrupt NAA20 function and support an essential
role for NatB-mediated N-terminal acetylation in human development and physiology.
All affected individuals display DD, ID, and microcephaly. We propose to use the
term <italic>NAA20</italic>-related syndrome to describe this
novel disorder caused by pathogenic <italic>NAA20</italic>
variants.</p>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supplementary information</title>
      <sec id="Sec8">
        <p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41436_2021_1264_MOESM1_ESM.docx"><caption><p>Supplementary Information</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="41436_2021_1264_MOESM2_ESM.xlsx"><caption><p>Supplementary Table 3</p></caption></media></supplementary-material>
</p>
      </sec>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p><bold>Publisher&#x2019;s note</bold> Springer Nature
remains neutral with regard to jurisdictional claims in published maps and
institutional affiliations.</p>
      </fn>
      <fn>
        <p>These authors contributed equally: Jennifer Morrison, Norah K. Altuwaijri,
Kirsten Br&#xF8;nstad and Henriette Aksnes.</p>
      </fn>
      <fn>
        <p>These authors contributed equally: Bryn D. Webb, Fowzan S. Alkuraya and
Thomas Arnesen.</p>
      </fn>
    </fn-group>
    <sec>
      <title>Supplementary information</title>
      <p>The online version contains supplementary material available at 10.1038/s41436-021-01264-0.</p>
    </sec>
    <ack>
      <title>Acknowledgements</title>
      <p>We thank Nina Glomnes, University of Bergen, for technical assistance, and
Kirsty McWalter, GeneDx, for establishing contact between the authors. The work was
supported by the Research Council of Norway (project 249843), the Norwegian Health
Authorities of Western Norway (project F-12540), and the Norwegian Cancer Society
(project 171752&#x2014;PR-2009-0222). B.D.W. is supported by NIH K08
HD086827.</p>
      <sec id="FPar1">
        <title>Author information:</title>
        <p id="Par20">Conceptualization: H.S.A., P.G.W., B.D.W., F.S.A., T.A. Data
curation: J.M., N.K.A., H.S.A., M.H., P.G.W., B.D.W. Formal Analysis: N.K.A.,
K.B., H.A., H.S.A., A.E. Funding acquisition: B.D.W., F.S.A., T.A.
Investigation: J.M., N.K.A., K.B., H.A., H.S.A., A.E., P.G.W., B.D.W. Project
administration: T.A. Resources: M.H., B.D.W. Supervision: P.G.W., B.D.W.,
F.S.A., T.A. Validation: A.E. Visualization: H.A. Writing&#x2014;original
draft: T.A. Writing&#x2014;review &amp; editing: J.M., N.K.A., H.A.,
H.S.A., M.H., P.G.W., B.D.W., F.S.A., T.A.</p>
      </sec>
    </ack>
    <notes notes-type="data-availability">
      <title>Data availability</title>
      <p>The <italic>NAA20</italic> variants with accession numbers
are available at LOVD: <ext-link ext-link-type="uri" xlink:href="https://databases.lovd.nl/shared/variants/0000763620#00014229">https://databases.lovd.nl/shared/variants/0000763620#00014229</ext-link> and <ext-link ext-link-type="uri" xlink:href="https://databases.lovd.nl/shared/variants/0000763619#00014229">https://databases.lovd.nl/shared/variants/0000763619#00014229</ext-link>.</p>
    </notes>
    <notes id="FPar2">
      <title>Ethics declaration</title>
      <p id="Par21">The study was conducted in accordance with the principles of the
Declaration of Helsinki and written informed consent was obtained from adult
participants and legal guardians of child participants. The study was approved
by the institutional review board (IRBs) at the Icahn School of Medicine at
Mount Sinai (13-00495) and the King Faisal Specialist Hospital and Research
Center (RAC 2121053).</p>
    </notes>
    <notes id="FPar3" notes-type="COI-statement">
      <title>Competing interests</title>
      <p id="Par22">The authors declare no competing
interests.</p>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aksnes</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ree</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Arnesen</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Co-translational, post-translational, and
non-catalytic roles of N-Terminal acetyltransferases</article-title>
          <source>Mol Cell.</source>
          <year>2019</year>
          <volume>73</volume>
          <fpage>1097</fpage>
          <lpage>1114</lpage>
          <pub-id pub-id-type="doi">10.1016/j.molcel.2019.02.007</pub-id>
          <pub-id pub-id-type="pmid">30878283</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arnesen</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Van Damme</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Polevoda</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Helsens</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Evjenth</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Colaert</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Proteomics analyses reveal the evolutionary
conservation and divergence of N-terminal acetyltransferases from yeast and
humans</article-title>
          <source>Proc Natl Acad Sci U S A.</source>
          <year>2009</year>
          <volume>106</volume>
          <fpage>8157</fpage>
          <lpage>8162</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.0901931106</pub-id>
          <pub-id pub-id-type="pmid">19420222</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Van Damme</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lasa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Polevoda</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Gazquez</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Elosegui-Artola</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>DS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>N-terminal acetylome analyses and functional
insights of the N-terminal acetyltransferase NatB</article-title>
          <source>Proc Natl Acad Sci U S A.</source>
          <year>2012</year>
          <volume>109</volume>
          <fpage>12449</fpage>
          <lpage>12454</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.1210303109</pub-id>
          <pub-id pub-id-type="pmid">22814378</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Starheim</surname>
              <given-names>KK</given-names>
            </name>
            <name>
              <surname>Arnesen</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Gromyko</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Ryningen</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Varhaug</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Lillehaug</surname>
              <given-names>JR</given-names>
            </name>
          </person-group>
          <article-title>Identification of the human
N(alpha)-acetyltransferase complex B (hNatB): a complex important for
cell-cycle progression</article-title>
          <source>Biochem J.</source>
          <year>2008</year>
          <volume>415</volume>
          <fpage>325</fpage>
          <lpage>331</lpage>
          <pub-id pub-id-type="doi">10.1042/BJ20080658</pub-id>
          <pub-id pub-id-type="pmid">18570629</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Polevoda</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Cardillo</surname>
              <given-names>TS</given-names>
            </name>
            <name>
              <surname>Doyle</surname>
              <given-names>TC</given-names>
            </name>
            <name>
              <surname>Bedi</surname>
              <given-names>GS</given-names>
            </name>
          </person-group>
          <article-title>Sherman F. Nat3p and Mdm20p are required for
function of yeast NatB Nalpha-terminal acetyltransferase and of actin and
tropomyosin</article-title>
          <source>J Biol Chem.</source>
          <year>2003</year>
          <volume>278</volume>
          <fpage>30686</fpage>
          <lpage>30697</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M304690200</pub-id>
          <pub-id pub-id-type="pmid">12783868</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Neri</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Lasa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Elosegui-Artola</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>D'Avola</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Carte</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Gazquez</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>NatB-mediated protein N-alpha-terminal acetylation
is a potential therapeutic target in hepatocellular carcinoma</article-title>
          <source>Oncotarget.</source>
          <year>2017</year>
          <volume>8</volume>
          <fpage>40967</fpage>
          <lpage>40981</lpage>
          <pub-id pub-id-type="doi">10.18632/oncotarget.17332</pub-id>
          <pub-id pub-id-type="pmid">28498797</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ametzazurra</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Larrea</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Civeira</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Prieto</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Aldabe</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Implication of human N-alpha-acetyltransferase 5 in
cellular proliferation and carcinogenesis</article-title>
          <source>Oncogene.</source>
          <year>2008</year>
          <volume>27</volume>
          <fpage>7296</fpage>
          <lpage>7306</lpage>
          <pub-id pub-id-type="doi">10.1038/onc.2008.332</pub-id>
          <pub-id pub-id-type="pmid">18794801</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oishi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yamayoshi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kozuka-Hata</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Oyama</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kawaoka</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>N-Terminal acetylation by NatB is required for the
shutoff activity of influenza A virus PA-X</article-title>
          <source>Cell Rep.</source>
          <year>2018</year>
          <volume>24</volume>
          <fpage>851</fpage>
          <lpage>860</lpage>
          <pub-id pub-id-type="doi">10.1016/j.celrep.2018.06.078</pub-id>
          <pub-id pub-id-type="pmid">30044982</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Croft</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Venkatakrishnan</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>N-terminal protein acetylation by NatB modulates the
levels of Nmnats, the NAD(+) biosynthetic enzymes in Saccharomyces
cerevisiae</article-title>
          <source>J Biol Chem.</source>
          <year>2020</year>
          <volume>295</volume>
          <fpage>7362</fpage>
          <lpage>7375</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.RA119.011667</pub-id>
          <pub-id pub-id-type="pmid">32299909</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sobreira</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Schiettecatte</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Valle</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Hamosh</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>GeneMatcher: a matching tool for connecting
investigators with an interest in the same gene</article-title>
          <source>Hum Mutat.</source>
          <year>2015</year>
          <volume>36</volume>
          <fpage>928</fpage>
          <lpage>930</lpage>
          <pub-id pub-id-type="doi">10.1002/humu.22844</pub-id>
          <pub-id pub-id-type="pmid">26220891</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rope</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Evjenth</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Xing</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Johnston</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Swensen</surname>
              <given-names>JJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Using VAAST to identify an X-linked disorder
resulting in lethality in male infants due to N-terminal acetyltransferase
deficiency</article-title>
          <source>Am J Hum Genet.</source>
          <year>2011</year>
          <volume>89</volume>
          <fpage>28</fpage>
          <lpage>43</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ajhg.2011.05.017</pub-id>
          <pub-id pub-id-type="pmid">21700266</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Myklebust</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Van Damme</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>St&#xF8;ve</surname>
              <given-names>SI</given-names>
            </name>
            <name>
              <surname>D&#xF6;rfel</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Abboud</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kalvik</surname>
              <given-names>TV</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Biochemical and cellular analysis of Ogden syndrome
reveals downstream Nt-acetylation defects</article-title>
          <source>Hum Mol Genet.</source>
          <year>2015</year>
          <volume>24</volume>
          <fpage>1956</fpage>
          <lpage>1976</lpage>
          <pub-id pub-id-type="doi">10.1093/hmg/ddu611</pub-id>
          <pub-id pub-id-type="pmid">25489052</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Van Damme</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Stove</surname>
              <given-names>SI</given-names>
            </name>
            <name>
              <surname>Glomnes</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Gevaert</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Arnesen</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>A Saccharomyces cerevisiae model reveals in vivo
functional impairment of the Ogden syndrome N-terminal acetyltransferase
NAA10 Ser37Pro mutant</article-title>
          <source>Mol Cell Proteomics.</source>
          <year>2014</year>
          <volume>13</volume>
          <fpage>2031</fpage>
          <lpage>2041</lpage>
          <pub-id pub-id-type="doi">10.1074/mcp.M113.035402</pub-id>
          <pub-id pub-id-type="pmid">24408909</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dorfel</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Fang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Crain</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Klingener</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Weiser</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lyon</surname>
              <given-names>GJ</given-names>
            </name>
          </person-group>
          <article-title>Proteomic and genomic characterization of a yeast
model for Ogden syndrome</article-title>
          <source>Yeast.</source>
          <year>2017</year>
          <volume>34</volume>
          <fpage>19</fpage>
          <lpage>37</lpage>
          <pub-id pub-id-type="doi">10.1002/yea.3211</pub-id>
          <pub-id pub-id-type="pmid">27668839</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Esmailpour</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Riazifar</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Donkervoort</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>VH</given-names>
            </name>
            <name>
              <surname>Madaan</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A splice donor mutation in NAA10 results in the
dysregulation of the retinoic acid signalling pathway and causes Lenz
microphthalmia syndrome</article-title>
          <source>J Med Genet.</source>
          <year>2014</year>
          <volume>51</volume>
          <fpage>185</fpage>
          <lpage>196</lpage>
          <pub-id pub-id-type="doi">10.1136/jmedgenet-2013-101660</pub-id>
          <pub-id pub-id-type="pmid">24431331</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <mixed-citation publication-type="other">Saunier C, St&#xF8;ve SI, Popp B, G&#xE9;rard B, Blenski M.
Expanding the phenotype associated with NAA10 related N-terminal acetylation
deficiency. Hum Mutat. 2016;37:755&#x2013;764.</mixed-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cheng</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Gottlieb</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Marchi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kleyner</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bhardwaj</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Rope</surname>
              <given-names>AF</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Phenotypic and biochemical analysis of an
international cohort of individuals with variants in NAA10 and
NAA15</article-title>
          <source>Hum Mol Genet.</source>
          <year>2019</year>
          <volume>28</volume>
          <fpage>2900</fpage>
          <lpage>2919</lpage>
          <pub-id pub-id-type="doi">10.1093/hmg/ddz111</pub-id>
          <pub-id pub-id-type="pmid">31127942</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cheng</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Dharmadhikari</surname>
              <given-names>AV</given-names>
            </name>
            <name>
              <surname>Varland</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Domingo</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kleyner</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Truncating variants in NAA15 are associated with
variable levels of intellectual disability, autism spectrum disorder, and
congenital anomalies</article-title>
          <source>Am J Hum Genet.</source>
          <year>2018</year>
          <volume>102</volume>
          <fpage>985</fpage>
          <lpage>994</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ajhg.2018.03.004</pub-id>
          <pub-id pub-id-type="pmid">29656860</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ward</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tai</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Morton</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Impens</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Van Damme</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Van Haver</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mechanisms of congenital heart disease caused by
NAA15 haploinsufficiency</article-title>
          <source>Circ Res.</source>
          <year>2021</year>
          <volume>128</volume>
          <fpage>1156</fpage>
          <lpage>1169</lpage>
          <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.120.316966</pub-id>
          <pub-id pub-id-type="pmid">33557580</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ritter</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Berger</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Deardorff</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Izumi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>KY</given-names>
            </name>
            <name>
              <surname>Medne</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Variants in NAA15 cause pediatric hypertrophic
cardiomyopathy</article-title>
          <source>Am J Med Genet A.</source>
          <year>2021</year>
          <volume>185</volume>
          <fpage>228</fpage>
          <lpage>233</lpage>
          <pub-id pub-id-type="doi">10.1002/ajmg.a.61928</pub-id>
          <pub-id pub-id-type="pmid">33103328</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>